报价延迟最少15分钟:2025/12/09 00:15 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
84.32 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.35/2.81
|
|
企业价值
50.69B
|
| 资产负债 |
|
每股账面净值
17.59
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
5.44B
|
|
每股收益
10.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
